Company predicts seven IND applications will be filed before the end of 1990. Five INDs have been filed so far this year. Three were sent to FDA in January -- for U-73975, an antineoplastic, and trospectomycin vaginal cream and suppository for bacterial vaginosis; one in February, for the lazaroid U-76006F for spinal cord injury; and one in March, for the oral anticonvulsant compound U-54494A. An IND for the I.V. form of the drug is slated for filing in the third quarter, and Upjohn is forecasting the filing of soluble CD4-PE40 for AIDS in the fourth quarter of 1990. Another soluble CD4 (U-84796) will get an IND filing in the first quarter of 1991.
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.